Exelixis, Inc. (EXEL) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

18/25

Growth 4 Margin 5 Expansion 3 Platform 1 Financial 5

latest quarter score

Earnings Reports

18
Exelixis (EXEL) Q2 2026: Zanza Franchise Pipeline Expands Across 7 Pivotal Trials, Guidance Trimmed
August 06, 2026
16
Exelixis (EXEL) Q4 2025: Cabo Franchise Grows 17% as Zanza Pipeline Accelerates
June 15, 2026
17
Exelixis (EXEL) Q1 2026: CaboMedics TRX Volume Up 14% as ZANSA Franchise Build Accelerates
May 06, 2026
21
Exelixis (EXEL) Q3 2025: CABO Neuroendocrine Tumor Demand Jumps 50% as GI Franchise Expansion Accelerates
November 05, 2025
20
Exelixis (EXEL) Q2 2025: CaboMedix NET Launch Captures 35% New Patient Share, Unlocking Franchise Expansion
July 29, 2025
20
Exelixis (EXEL) Q1 2025: Cabo Franchise Grows 36% as NET Launch Expands Oncology Opportunity
July 06, 2025

Browse all companies